Pharma BD Deal Intelligence
Gilead's $21B, 108%-premium buy of Immunomedics landed Trodelvy, the first approved anti-Trop-2 ADC, and the underlying platform—now a genuine standard-of-care asset in triple-negative breast cancer. A steep price for a single molecule, but Trodelvy's expanding label has largely justified it.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Gilead Sciences will pay 21 billion dollars to acquire Immunomedics and gain control of Trodelvy, a recently approved antibody-drug conjugate for metastatic…
Gilead Sciences agreed to acquire cancer-drug developer Immunomedics for 21 billion dollars in cash, the U.S. drugmaker's biggest deal yet, to bolster its…
Gilead's $21 billion purchase of Immunomedics boosts ADC field. The deal gives Gilead Trodelvy, a recently approved antibody-drug conjugate, and a platform for…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Gilead Sciences acquired Immunomedics for approximately $21 billion ($88.00 per share in cash), a 108% premium, gaining Trodelvy (sacituzumab govitecan), the first FDA-approved anti-Trop-2 antibody-drug conjugate for metastatic triple-negative breast cancer, along with Immunomedics' proprietary ADC platform technology.
83K US cases/yr · $4.0B Global Urothelial/Bladder Cancer Market (2024)
Urothelial carcinoma is the most common bladder cancer subtype. Treatment has been transformed by enfortumab vedotin + pembrolizumab as a new standard in advanced disease.
Seagen/Pfizer (Padcev, $3B+) + Merck (Keytruda) emerging as standard 1L combo. Gilead (Trodelvy) competes in later lines.
45K US cases/yr · $1.1B Global TNBC Market (2024)
Triple-negative breast cancer (TNBC) accounts for 10-15% of invasive breast cancers and is defined by absence of ER, PR, and HER2 expression. It is more common in younger women, Black women, and BRCA1 carriers, with higher rates of early recurrence and visceral metastasis. Treatment historically relied on cytotoxic chemotherapy; the landscape now includes PD-1 inhibitors for PD-L1-positive disease, PARP inhibitors for BRCA-mutant disease, and the Trop-2-directed ADC sacituzumab govitecan in metastatic disease.
Gilead (Trodelvy, $1.5B+) is the ADC leader in TNBC. Merck (Keytruda + chemo) dominates PD-L1+ 1L. AZ/Daiichi Sankyo (Enhertu) expanding into HER2-low TNBC.
40K US cases/yr · $12.0B Global metastatic breast cancer therapeutics market 2020 · ~$1.6B Trodelvy 2023 worldwide net sales (post-acquisition validation)
Triple-negative breast cancer (TNBC) accounts for approximately 10-15% of all breast cancer diagnoses, translating to roughly 30,000-40,000 new U.S. cases annually out of ~290,000 total invasive breast cancers. TNBC is defined by absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 amplification, removing eligibility for endocrine therapy and HER2-directed agents. mTNBC carries the poorest prognosis among breast cancer subtypes — historical median overall survival in second-line metastatic disease was 6-9 months prior to Trodelvy approval. Urothelial cancer (bladder cancer) accounts for ~83,000 new U.S. cases annually, with metastatic disease representing the highest-mortality subset where post-platinum/post-IO options were limited prior to the 2021 accelerated approval of Trodelvy in mUC. Trop-2 (TACSTD2, tumor-associated calcium signal transducer 2) is overexpressed in >85% of TNBC and >80% of urothelial cancers, providing a broad-expression antigen target. Trodelvy (sacituzumab govitecan) is the first FDA-approved anti-Trop-2 antibody-drug conjugate (ADC), pairing a humanized anti-Trop-2 IgG with the topoisomerase I inhibitor SN-38 via a hydrolyzable CL2A linker — a high drug-antibody-ratio design with bystander effect. Pricing for ADC therapeutics ranges $13K-22K per month WAC. Trodelvy is the cornerstone asset of the Immunomedics acquisition.
The mTNBC competitive landscape transformed dramatically between 2020 and 2024. At deal signing, Trodelvy (sacituzumab govitecan, anti-Trop-2 ADC) had just received accelerated FDA approval (April 2020) for ≥3rd line mTNBC and was the first ADC approved for breast cancer outside of HER2-targeted disease. Tecentriq (atezolizumab, anti-PD-L1, Roche) plus nab-paclitaxel was approved 2019 for PD-L1+ mTNBC but later withdrew the indication after IMpassion131 missed primary endpoints. Keytruda (pembrolizumab, anti-PD-1, Merck) plus chemotherapy was approved 2020 for PD-L1+ mTNBC (KEYNOTE-355) and remains a first-line standard. Standard chemotherapies include capecitabine (Xeloda), eribulin (Halaven, Eisai), and gemcitabine. Trodelvy expanded to HR+/HER2- breast cancer (TROPiCS-02, 2023 approval) and metastatic urothelial carcinoma (TROPHY-U-01, 2021 accelerated approval, 2024 voluntary withdrawal after TROPiCS-04 confirmatory miss). Competitive Trop-2 ADCs include Daiichi/AstraZeneca's datopotamab deruxtecan (Dato-DXd) — Phase 3 TROPION-Breast01 mixed readout 2024 — and Merck/Kelun's MK-2870 (sacituzumab tirumotecan, Phase 3). HER3-DXd (Daiichi) targets a distinct antigen. The acquisition gave Gilead immediate ADC platform leadership and a multi-tumor expansion roadmap.
Gilead Sciences agrees to acquire Immunomedics for $88/share (~$21B), gaining Trodelvy (sacituzumab govitecan), the first anti-Trop-2 ADC approved for metastatic triple-negative breast cancer.
Gilead and its acquisition subsidiary commence tender offer for all outstanding Immunomedics shares at $88/share in cash.
Gilead completes the tender offer and short-form merger with Immunomedics in just 40 days from announcement, one of the fastest large pharma deals. Immunomedics delists from Nasdaq.
FDA grants accelerated approval for Trodelvy in metastatic urothelial cancer, expanding the addressable market beyond triple-negative breast cancer.
Gilead acquires remaining worldwide rights to Trodelvy from Everest Medicines, consolidating global commercial control of the ADC franchise.
Trodelvy reaches blockbuster status with $1.06B in 2023 full-year sales, up 56% from $680M in 2022, driven by HR+/HER2- breast cancer expansion.
Gilead paid $21B for a single-product company and Trodelvy has reached blockbuster status ($1.06B in 2023). The ADC platform extends beyond TNBC into urothelial, HR+/HER2- breast, and lung cancers. Speed of close (40 days) was remarkable. The bet was on the ADC mechanism class, and it is paying off as the ADC field expands industry-wide.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Immunomedics Inc. (this deal) | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
| Gilead Sciences Inc. / Myogen Inc. | 2006 | $2.5B | 62 |
← Browse all deals · How we score deals
More: 2020 deals · Gilead Sciences Inc. deals · Oncology deals